Minakem-flap
Minakem-flap

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): AM3101

            Therapeutic Area: Musculoskeletal Product Name: AM3101

            Highest Development Status: Preclinical Product Type: Undisclosed

            Partner/Sponsor/Collaborator: Photon Fund

            Deal Size: $4.0 million Upfront Cash: Undisclosed

            Deal Type: Financing March 25, 2021

            Details:

            The proceeds from the financing will enable Amplicore to complete the preclinical development of its two leading products, AM3101 and AM1101, and position the company for the next round of financing.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Diclofenac Epolamine

            Therapeutic Area: Musculoskeletal Product Name: Epoladerm

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Virpax Pharmaceuticals

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement March 10, 2021

            Details:

            Under the terms of this agreement, Charles River Laboratories will perform seven preclinical animal studies including method, dosage, and toxicity as part of the required the U.S. FDA enabling trials for an Investigational New Drug Application for Epoladerm.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Micronized umbilical cord tissue

            Therapeutic Area: Musculoskeletal Product Name: Signature Cord Prime

            Highest Development Status: Preclinical Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable February 16, 2021

            Details:

            U.S. Food and Drug Administration (FDA) has approved an IND Application to proceed with the study of Signature Cord Prime™ in patients with symptomatic osteoarthritis (OA) of the knee with our Principal Investigator.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Parathyroid Hormone

            Therapeutic Area: Musculoskeletal Product Name: PTH

            Highest Development Status: Preclinical Product Type: Peptide

            Partner/Sponsor/Collaborator: BofA Securities

            Deal Size: $69.0 million Upfront Cash: Undisclosed

            Deal Type: Series E Financing December 10, 2020

            Details:

            Rani Therapeutics platform technology converts injectable drugs like PTH and adalimumab into pills. Rani has conducted early human studies with adalimumab and exenatide to confirm high bioavailability with the Rani delivery approach.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): KER-012

            Therapeutic Area: Musculoskeletal Product Name: KER-012

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable September 11, 2020

            Details:

            In Preclinical Studies, KER-012 Increased Trabecular Bone by Reducing Bone Catabolism and Enhancing Anabolism.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Calcium Alpha-Ketoglutarate

            Therapeutic Area: Musculoskeletal Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable September 02, 2020

            Details:

            The multi-year study, conducted by the Buck Institute for Research on Aging in aged mice, found that calcium alpha-ketoglutarate (Ca-AKG), a stable form of alpha-ketoglutarate, promotes longer, healthier life associated with a decrease in levels of inflammatory cytokines.